TABLE 2.
Overall median time‐on‐treatment in patients who received first‐ and second‐line treatments
| Total (n = 324) | p | Group A (n = 126) | p | Group B (n = 198) | p | |
|---|---|---|---|---|---|---|
| Overall | 25.9 (23.5–30.4) | 35.4 (27.7–45.6) | 20.8 (19.4–24.0) | |||
| Age | 0.627 | 0.662 | 0.546 | |||
| <65 | 26.4 (22.7–31.0) | 33.8 (26.4–NA) | 21.7 (19.9–30.5) | |||
| ≥65 | 24.2 (20.8–33.7) | 41.1 (31.0–NA) | 20.3 (18.0–23.5) | |||
| Sex | 0.267 | 0.671 | 0.047 | |||
| Men | 24.4 (21.3–30.4) | 36.4 (26.2–NA) | 19.4 (16.7–21.7) | |||
| Women | 27.6 (25.0–33.9) | 35.4 (27.6–48.5) | 24.0 (20.5–31.0) | |||
| ECOG PS | 0.023 | 0.667 | 0.092 | |||
| 0 or 1 | 26.5 (24.2–31.0) | 33.9 (27.7–47.0) | 21.5 (19.9–25.0) | |||
| ≥2 | 19.8 (14.2–NA) | 20.1 (14.2–NA) | 16.9 (11.5–NA) | |||
| Stage§ | 0.251 | 0.029 | 0.294 | |||
| 3 and 4A | 27.4 (24.0–34.2) | 41.1 (35.4–NA) | 21.5 (19.4–27.4) | |||
| 4B | 22.0 (21.3–27.1) | 26.5 (24.4–NA) | 19.9 (17.6–21.9) | |||
| Smoking | 0.867 | 0.584 | 0.175 | |||
| Never | 26.9 (24.7–31.0) | 33.9 (27.4–48.5) | 22.5 (20.3–30.4) | |||
| Former | 24.7 (21.4–32.8) | 33.8 (25.3–NA) | 20.3 (17.6–27.4) | |||
| Current | 22.2 (14.3–NA) | 47.0 (22.7–NA) | 12.3 (8.9–NA) | |||
| Tissue type | 0.004 | 0.131 | 0.001 | |||
| Adenocarcinoma | 26.2 (23.5–30.8) | 35.4 (27.7–45.6) | 21.4 (19.8–24.7) | |||
| Others¶ | 14.7 (8.9–NA) | 27.1 (14.7–NA) | 10.5 (5.5–NA) | |||
| EGFR mutation | 0.813 | 0.659 | 0.136 | |||
| Del19 | 26.9 (23.5–31.0) | 40.9 (27.8–49.5) | 21.4 (20.0–26.9) | |||
| L858R | 26.2 (21.4–34.0) | 26.5 (25.0–NA) | 24.0 (19.4–NA) | |||
| Others† | 23.5 (17.1–47.0) | 39.5 (33.9–NA) | 17.2 (13.4–24.7) | |||
| # of metastatic organs | 0.005 | 0.029 | 0.004 | |||
| 0–1 | 30.8 (25.0–40.9) | 45.6 (39.5–NA) | 24.7 (21.5–34.0) | |||
| 2–3 | 21.7 (20.1–27.5) | 31.0 (26.4–42.4) | 19.4 (16.4–21.4) | |||
| 4 or more | 20.3 (16.2–48.5) | 24.4 (19.6–NA) | 16.2 (13.0–NA) | |||
| Adrenal gland meta. | 0.963 | 0.942 | 0.677 | |||
| Yes | 25.3 (23.5–29.0) | 33.9 (27.4–45.6) | 16.2 (10.7–NA) | |||
| No | 32.8 (18.8–NA) | 41.1 (32.8–NA) | 21.4 (19.8–24.7) | |||
| Liver meta. | <0.001 | <0.001 | <0.001 | |||
| Yes | 19.1 (15.5–24.4) | 21.4 (19.1–32.8) | 13.8 (7.4‐NA) | |||
| No | 27.5 (24.8–33.9) | 42.1 (33.9–NA) | 21.4 (20.0–25.0) | |||
| Bone meta. | 0.012 | 0.035 | 0.006 | |||
| Yes | 21.4 (20.1–25.9) | 27.7 (24.4–41.1) | 19.4 (17.2–20.8) | |||
| No | 29.0 (25.3–35.4) | 42.1 (35.4–NA) | 23.5 (20.3–31.0) | |||
| Brain meta. | 0.482 | 0.543 | 0.732 | |||
| Yes | 24.4 (21.4–30.4) | 33.7 (25.3‐NA) | 21.7 (19.4–30.5) | |||
| No | 27.1 (23.5–33.8) | 36.4 (27.4–49.5) | 20.3 (18.0–24.7) | |||
| Type of brain meta. | 0.534 | 0.812 | 0.276 | |||
| Single parenchymal | 25.3 (20.3–NA) | 42.4 (13.5–NA) | 21.4 (20.3–NA) | |||
| Multiple +/− seeding | 24.4 (21.4–29.0) | 33.7 (24.8–NA) | 19.4 (17.1–24.9) | |||
| New lesion or aggravation of brain meta. | 0.005 | 0.148 | 0.127 | |||
| Yes | 21.4 (18.0–25.9) | 27.1 (20.1–49.5) | 19.9 (14.3–23.5) | |||
| No | 27.6 (25.0–33.8) | 39.5 (31.0–48.5) | 21.7 (19.8–29.0) | |||
| Dose adj. for afatinib | 0.047 | 0.503 | 0.072 | |||
| Yes | 27.4 (23.5–33.9) | 35.4 (27.6–49.5) | 21.7 (20.3–30.5) | |||
| No | 25.0 (19.7–29.0) | 33.8 (26.5–NA) | 18.9 (15.8–24.9) |
Data are presented as months (95% confidence intervals), unless otherwise stated.
Patients in group A received sequential treatment with afatinib and osimertinib, while patients in group B received other therapies following first‐line afatinib treatment.
Abbreviations: adj., adjustment; Del19, deletion 19; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; meta., metastasis; NA, not‐available.
Tumor stage was classified based on 8th edition of the American Joint Committee on Cancer staging system.
Other tissue types included squamous cell carcinoma in two patients, adenosquamous cell carcinoma in two patients, and non‐small cell lung cancer in three patients.
Patients not presenting with EGFR Del19 and L858R mutations, including de novo T790M mutation, are classified as the “Others” group.